In addition, increased level of soluble B2M has been observed in the cerebral spinal fluid of patients with HIV-associated dementia [28], Parkinson’s diseases [29] and Alzheimer’s disease [30]. This evidence concerns the gene B2M and early-onset autosomal dominant Alzheimer disease.